Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives

ISSN： 1479-6694

Source： Future Oncology, Vol.7, Iss.4, 2011-04, pp. : 551-558

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?

By Aragon-Ching Jeanny B

Future Oncology, Vol. 9, Iss. 5, 2013-05 ,pp. : 619-622

Future Medicine

Access to resources Recommend Favorite

Molecular mechanisms of castration-resistant prostate cancer progression

By Dutt Smitha S Gao Allen C

Future Oncology, Vol. 5, Iss. 9, 2009-11 ,pp. : 1403-1413

Future Medicine

Access to resources Recommend Favorite

The role of enzalutamide in the treatment of castration-resistant prostate cancer

By Rawlinson Alex Mohammed Aza Miller Marek Kunkler Roger

Future Oncology, Vol. 8, Iss. 9, 2012-09 ,pp. : 1073-1081

Future Medicine

Access to resources Recommend Favorite

Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 10, 2009-12 ,pp. : 1040-1045

Bentham Science Publishers

Access to resources Recommend Favorite

New Therapeutic Strategies for Castration-Resistant Prostate Cancer

Recent Patents on Anti-Cancer Drug Discovery, Vol. 6, Iss. 3, 2011-09 ,pp. : 373-383

Bentham Science Publishers

Access to resources Recommend Favorite